Annidis Corporation to apply to TSX Venture Exchange for Warrant Extension

OTTAWA, Dec. 10, 2013 /CNW/ - Annidis Corporation (TSX Venture: RHA) ("Annidis" or the "Corporation"), creator of the Annidis RHA™, is pleased to announce that it will be submitting an application to the TSX Venture Exchange ("TSXV") for approval to extend the expiry date of certain issued and outstanding common share purchase warrants.

Warrant Extension

In accordance with TSXV Policy 4.1, Annidis Corporation reports that it will submit an application to the TSXV to extend the term of 3,531,250 warrants which were issued by the Corporation on June 9, 2011 in connection with the completion of the Corporation's Qualifying Transaction ("QT"). The warrants are presently exercisable at prices of $0.30 and $0.40 per common share and are set to expire between December 18, 2013 and November 4, 2014. The Corporation is applying to extend the expiry date of the warrants to September 30, 2016. All other terms of the warrants, including the exercise prices, will remain unchanged. The proposed warrant extensions have been approved by the Corporation's board of directors, subject to the receipt of TSXV approval.

About Annidis Corporation

Annidis (TSXV: RHA) has developed and is marketing a new imaging platform technology based on Multi-Spectral Imaging (MSI). This new technology is opening a new frontier in disease identification and its management. The Annidis MSI technology allows eye-care professionals to view non-invasively the deepest areas of the eye aiding eye care professionals in the early identification and treatment of debilitating eye diseases. The Company's existing RHA 2020-U Gold, used by eye care professionals as a broad based tool for detecting early-onset of eye related diseases such as Dry AMD, has a potential market of over 20,000 clinics in North America. The RHA Platinum MD will further strengthen the value proposition allowing doctors to visualize choroidal and retinal vasculature non-invasively. The RHA Platinum MD has global market potential of more than 100,000 Ophthalmologists.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Annidis Corporation

For further information:

Gerald Slemko,
Chief Executive Officer
Annidis Corporation
(519) 858-1582 ext. 239
geralds@annidis.com

Babak Pedram
Investor Relations
Virtus Advisory Group Inc.
416-995-8651
bpedram@virtusadvisory.com